Dr. Reddy’s had hoped to start moving beyond an FDA warning letter that lambasted three of its India plants for data integrity and other issues in 2015, but those hopes were stymied in the latest ...
Dr. Reddy’s has spent nearly five years trying to get out from under a warning letter for an important API plant in India but has yet to shake off all of the FDA’s concerns. In fact, a new FDA filing ...
HYDERABAD, India--(BUSINESS WIRE)--Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced that it has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results